- Silo Pharma, Inc. announced the closing of a **registered direct offering** of **2,857,143 shares** of common stock at a purchase price of **$0.875 per share**.  **[1514183_0001213900-25-094711_ea025946401ex99-2_silo.htm:0]** **[1514183_0001213900-25-094711_ea0259464-8k_silo.htm:1]** 
- The offering generated approximately **$2.5 million** in gross proceeds for the company.  **[1514183_0001213900-25-094711_ea025946401ex99-2_silo.htm:0]** **[1514183_0001213900-25-094711_ea0259464-8k_silo.htm:1]** 
- Concurrently, the company issued unregistered warrants to purchase up to **2,857,143 shares** of common stock at an exercise price of **$0.75 per share**, which are immediately exercisable and expire five years from the effective date of a registration statement for resale.  **[1514183_0001213900-25-094711_ea025946401ex99-2_silo.htm:0]** **[1514183_0001213900-25-094711_ea0259464-8k_silo.htm:1]** 
- The net proceeds from the offering are intended for **working capital and general corporate purposes**.  **[1514183_0001213900-25-094711_ea025946401ex99-2_silo.htm:0]** **[1514183_0001213900-25-094711_ea0259464-8k_silo.htm:1]** **[1514183_0001213900-25-094711_ea025946401ex10-1_silo.htm:37]** 
- H.C. Wainwright & Co. acted as the exclusive placement agent, receiving a **7.5% cash fee** and a **1.0% management fee** of the gross proceeds, and warrants to purchase up to **214,285 shares** at an exercise price of **$1.0938 per share**.  **[1514183_0001213900-25-094711_ea0259464-8k_silo.htm:2]**

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering

- Silo Pharma, Inc. announced on **September 3, 2025**, that **IP Australia** (the Australian Patent Office) has granted patent number **2020271839** to its research and licensing partner Columbia University for an invention exclusively licensed to Silo.  **[1514183_371054198b234d34a3c650b9a3882776_0]** 
- This patent reinforces protection for Silo’s lead asset, **SPC-15**, an intranasal treatment targeting **post-traumatic stress disorder (PTSD)**.  **[1514183_371054198b234d34a3c650b9a3882776_0]** 
- According to Silo CEO Eric Weisblum, this patent strengthens the company's global intellectual property portfolio for **SPC-15** and supports plans for its clinical trial development as an innovative therapeutic for PTSD.  **[1514183_371054198b234d34a3c650b9a3882776_0]** 
- **SPC-15** is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders and has potential eligibility for the FDA’s streamlined **505(b)(2)** regulatory pathway.  **[1514183_371054198b234d34a3c650b9a3882776_0]**

Silo Pharma (SILO)